[Ip-health] Phase III
gmcfiar at gmail.com
Sun Aug 24 05:41:19 PDT 2014
Here's an analysis complaining that phase III studies cost a lot--and maybe they should what--stop them? As the risk of finding out the new drug is only marginally useful or perhaps more dangerous than earlier trials suggested and therefore--pharma could lose money? Is that the upshot of this paper in your view?
Is there any rebuttal to this pernicious nonsense?
More information about the Ip-health